Premium
Targeted Small‐Molecule Conjugates: The Future is Now
Author(s) -
Dal Corso Alberto
Publication year - 2020
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.202000507
Subject(s) - small molecule , bifunctional , immunotherapy , drug discovery , nanotechnology , drug , targeted therapy , conjugate , computational biology , medicine , computer science , cancer , bioinformatics , chemistry , pharmacology , biology , materials science , biochemistry , mathematics , catalysis , mathematical analysis
In recent years, novel classes of small hetero‐bifunctional compounds have been developed as tools for the treatment of cancer and other diseases through different approaches, from radio/chemotherapy and imaging to immunotherapy and protein degradation. Within this growing research area, progresses in ligand‐screening procedures and hit‐to‐lead optimizations, together with advances in drug‐release technologies, are paving the way to the future treatment of a broad range of pathologies with small targeted therapeutics.